Tutti gli studi
Non ancora in fase di reclutamentoFASE4INTERVENTISTICO

Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT)

This study is for people living with HIV who are also taking medication for opioid addiction, like methadone or buprenorphine. We're testing a new HIV medicine called Dovato (which is Dolutegravir/Lamivudine). The main goal is to check if Dovato keeps the HIV virus suppressed (under control) when people switch from their usual HIV treatment. We also want to find out about any side effects from Dovato, if it affects their opioid addiction treatment doses, and how satisfied they are with the new medicine. We're especially interested in how Dovato works for people who might not have been studied much before, including those from Indigenous backgrounds, younger women, or those who use recreational drugs.

A colpo d'occhio

Stato
Non ancora in fase di reclutamento
Fase
FASE4
Sponsor
Saskatchewan Health Authority - Regina Area
Obiettivo di iscrizione
40
Inizio
30 Set 2024
Completamento stimato
31 Oct 2027

Di cosa tratta questo studio?

This study is for people living with HIV who are currently taking medication to help manage opioid addiction. These medications might include treatments like methadone or buprenorphine. The study focuses on an HIV medicine called Dovato (you might hear its ingredients, Dolutegravir and Lamivudine, mentioned too). If you're currently taking other HIV medicines and your HIV is well controlled, this study looks at what happens if you switch to Dovato instead.

The main aim is to see if Dovato continues to keep your HIV under control after you switch from your current treatment. The researchers will also be carefully watching for any side effects and seeing if Dovato affects the doses of your opioid addiction medication. They'll also check how happy people are with Dovato compared to their previous HIV treatment.

This research is particularly important because there isn't much information yet about how Dovato works in people living with HIV who are also receiving opioid addiction treatment, especially for certain groups like younger women, people from Indigenous backgrounds, or those who might use recreational drugs. This study hopes to fill those gaps in our understanding.

Punti chiave

  • Switching HIV medication to Dovato for people on opioid addiction treatment.
  • Checking if Dovato keeps HIV under control.
  • Monitoring for side effects and impacts on opioid addiction treatment.
  • Study lasts for about 11 months with regular check-ups.
  • Aims to learn more about Dovato for groups often understudied.

Chi può essere idoneo?

To join this study, you need to be at least 18 years old and living with HIV-1. Your HIV must be well controlled, meaning the virus in your blood is at a very low level for at least three months. You also need to have been taking medication for opioid addiction (like methadone or buprenorphine) for at least three months and your doctor believes you are stable on this treatment.

There are several reasons you might not be able to join. For example, if you have certain liver or kidney problems, or if you're pregnant or planning to get pregnant. Also, if you have hepatitis B, or if you've had an allergic reaction to any ingredients in Dovato before, you wouldn't be able to take part. It's important that Dovato doesn't interfere with any other medicines you're taking.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. Hai 18 anni o più?
  2. Do you have HIV-1 that is currently well controlled?
  3. Are you taking medication for opioid addiction (like methadone/buprenorphine) and stable on it for at least 3 months?
  4. Are you not pregnant or planning to become so?
  5. Do you not have certain liver or kidney issues, or hepatitis B?
  6. Have you never had a serious allergic reaction to ingredients in Dovato?
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

If you decide to take part in this study, you'll be switching from your current HIV medication to Dovato. During the study, which lasts for 48 weeks (about 11 months), you'll have regular appointments. At these appointments, you’ll complete several questionnaires about your health and how you're feeling. You'll also have blood tests, urine tests to check for certain substances, and a review of all your medications and any side effects you might be experiencing. You'll have an ECG (a heart check) at the start of the study and again at the end, and a physical exam. Your alcohol use will also be discussed. The study team will guide you through all these steps.

Rischi e benefici potenziali

Taking part in this study could offer you the benefit of trying a new HIV medication that might be simpler to take. However, like all medicines, Dovato can have side effects, and some people might need to adjust their opioid addiction treatment doses. There's also a chance that the new medication might not keep your HIV as well controlled as your previous treatment. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Luoghi (1)

  • Saskatchewan Health Authority
    Codice postale verificato
    Regina, Canada

Domande comuni

What is Dovato?

Dovato is an HIV medicine that contains two drugs, Dolutegravir and Lamivudine, in one tablet.

Perché questo studio è importante?

It helps us understand how Dovato works for people living with HIV who are also on opioid addiction treatment, especially those not often included in past studies.

Will I still take my opioid addiction medication?

Yes, you will continue your opioid addiction treatment as prescribed, and the study will check if Dovato affects its dosage.

Cosa succede se avverto effetti collaterali?

The study team will carefully monitor you for any side effects and address them with you.

Posso abbandonare lo studio se cambio idea?

Yes, you can leave the study at any point without it affecting your future medical care.

Come saperne di più

Jones Kalyniuk, MSc

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Interessato a partecipare?

Registrati per ricevere aggiornamenti

Condividi i tuoi dettagli e il team di ricerca per "Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) Fr…" ti contatterà se potresti essere idoneo. Parla sempre con il tuo medico prima di accettare di partecipare.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.